Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPocc Trial: Intravenous vs Intraperitoneal Carboplatin with Weekly Paclitaxel in Ovarian/Fallopian Tube/Peritoneal Cancer
jRCTs031180141Phase 3Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of paclitaxel and carboplatin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Progression-free survival. Started Jul 2010; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCTs031180141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180141.